D005977Chemicals & DrugsD02.241.081.337.351680.990028Glutaratesprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1.409320.005766296research area of0.7748740.005824378subject area forMedicine-Rheumatology29288433Yamashita H, Sun CCPharmaceutical researchImproving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer. Pharm Res. 2017 12 29; 35(1):4.Pharm Res2017-12-29T00:00:002017Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer.32705421Yamashita H, Sun CCPharmaceutical researchMaterial-Sparing and Expedited Development of a Tablet Formulation of Carbamazepine Glutaric Acid Cocrystal- a QbD Approach. Pharm Res. 2020 Jul 23; 37(8):153.Pharm Res2020-07-23T00:00:002020Material-Sparing and Expedited Development of a Tablet Formulation of Carbamazepine Glutaric Acid Cocrystal- a QbD Approach.11875161Piatt JH, Frim DPediatricsGlutaric aciduria type 1 and nonaccidental head injury. Pediatrics. 2002 Mar; 109(3):554.Pediatrics2002-03-01T00:00:002002Glutaric aciduria type 1 and nonaccidental head injury.Medicine-Hematology and OncologyNeurological SurgeryBrandonFaubertBrandon Faubert41.7886000000000087.598699999999994090Faubert, BrandonAssistant Professor36847506Gunn K, Myllykoski M, Cao JZ, Ahmed M, Huang B, Rouaisnel B, Diplas BH, Levitt MM, Looper R, Doench JG, Ligon KL, Kornblum HI, McBrayer SK, Yan H, Duy C, Godley LA, Koivunen P, Losman JACancer discovery(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Cancer Discov. 2023 06 02; 13(6):1478-1497.Cancer Discov2023-06-02T00:00:002023(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.University of ChicagoLucyGodley22VmD60QeczMknJtY0fp/Cv/+94=Lucy Godley41.78927490000000-87.601250000000001017Godley, LucyProfessorDavid M.FrimDavid M. Frim41.78927490000000-87.601250000000001527Frim, David M.Clinical ProfessorChangSunChang Sun41.78927490000000-87.601250000000002024Sun, ChangAmyWeinmannAmy Weinmann41.7886000000000087.598699999999994533Weinmann, AmyProfessortrue1true1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Clinical ProfessorClinical Professor101022680765Pollyea DA, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Vasanthakumar A, Abdel-Wahab O, Levine R, Godley LA, Medeiros BCLeukemia & lymphoma2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma. 2013 Feb; 54(2):408-10.Leuk Lymphoma2012-07-09T00:00:0020122-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.